Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers

Completed · Phase 2 · Has a placebo group

Conditions studied: Foot Ulcer, Diabetic, Diabetic Foot

In brief

The purpose of this study is to assess if the experimental drug, DSC127, is safe, how well it can be tolerated, and how different doses effect the healing of the chronic foot ulcers in diabetic subjects.

Key facts

Study ID

NCT00796744

Run by

US Biotest, Inc.

People needed

78

Starts

2008-10-01

Expected to finish

2011-05-01

Last updated by the study team

2012-09-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have at least one chronic non-healing Wagner Grade 1 or Grade 2 plantar neuropathic diabetic ulcer between 1.0-6.0 cm2 on the midfoot or forefoot, including the toes but excluding the heel.
• ABI greater than 0.7 for neuroischemic or greater than 0.8 for neuropathic DU
• TcPO2 greater than 40 mm Hg or great toe systolic pressure greater than 50 mmHg
• Type I or Type II diabetes under metabolic control
• Female subjects must have a negative pregnancy test and be willing to use acceptable method of birth control for the duration of the study

You may not qualify if…

• Exposure to any investigational product within the last 30 days, or have known hypersensitivity to any of the study medication components
• Chronic renal insufficiency and/or chronic liver dysfunction
• Resting blood pressure (at the time of the initial visit of the Screening Period) which exceeds 160 systolic and/or 90 diastolic mmHg on 3 consecutive readings at least 15 minutes apart
• Malignancy of any kind
• Receiving hemodialysis or CAPD
• Current history of drug abuse, and/or known to be HIV positive
• Prior radiation therapy of the foot under study
• Current use of corticosteroids (within past 8 weeks), immunosuppressants (within past 8 weeks), or use of a biologic agent to include growth factors and skin equivalents (Regranex, Apligraft, or Dermagraft) in the past 90 days
• Ulcer is deemed clinically infected and requires topical antimicrobials or agents known to affect wound healing, or the subject has been taking systemic antibiotics for more than 7 days for any reason
• Sickle-cell anemia, Raynaud's or other peripheral vascular disease
• Wagner Grade 3 or higher DU, deep abscess or infection of the joint or tendon, or gangrene or osteomyelitis
• An EKG with a marked baseline prolongation of QT/QTc interval

Where it is running

• Southern Arizona VA Health Care System — Tucson, Arizona, United States
• Southern Arizona Limb Salvage Alliance (SALSA) — Tucson, Arizona, United States
• Bay Area Footcare — Castro Valley, California, United States
• University of California, San Diego — San Diego, California, United States
• Olive View - UCLA Medical Center — Sylmar, California, United States
• Passavant Area Hospital — Jacksonville, Illinois, United States
• Georgetown University Medical Center — Georgetown, Maryland, United States
• Boston University School of Medicine — Boston, Massachusetts, United States
• Eastern Carolina Foot & Ankle Specialists — Greenville, North Carolina, United States
• Warren General Hospital Wound Clinic — Warren, Pennsylvania, United States
• Renaissance Hospital Dallas — Dallas, Texas, United States
• Professional Education and Research Institute — Roanoke, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.